castlecreekbio产品代理
castlecreekbio产品代理
走在个性化生物制剂的前沿
Castle Creek Biosciences, Inc. 是一家临床阶段的细胞和基因治疗公司，专注于为缺乏可用治疗方案的罕见疾病患者开发和商业化疾病修饰疗法。基于我们专有的自体成纤维细胞技术平台，我们的个性化生物制剂方法与众不同。通过从患者自己的皮肤中提取成纤维细胞，我们创造了与每个患者的独特生物学相兼容的局部治疗方法，并有可能解决疾病的根本原因。
我们的任务利用我们专有的自体成纤维细胞技术平台和制造经验背后的科学，创造转化细胞和基因疗法，并改善患有罕见疾病的患者的生活，这些罕见疾病没有可用的疾病修饰疗法。
我们对生命科学创新的承诺
Castle Creek Biosciences 是 Paragon Biosciences 的投资组合公司。
The Leader in Autologous Fibroblast Therapies
At the forefront of personalized biologics
Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company, is focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Our approach to personalized biologics is distinctive based on our proprietary, autologous fibroblast technology platform. By extracting fibroblast cells from a patient’s own skin, we create localized treatments that are compatible with the unique biology of each patient and
have the potential to address the underlying cause of disease.
Our Mission
To leverage the science behind our proprietary, autologous fibroblast technology platform and manufacturing experience to create transformative cell and gene therapies and improve the lives of patients suffering from rare diseases for which there are no disease-modifying treatments available.
Our Commitment to Life Science Innovation
Castle Creek Biosciences is a portfolio company of Paragon Biosciences.
Paragon is a global life science leader that creates, builds and funds innovative biology-based companies in three key areas: cell and gene therapy, adaptive biology and advanced biotechnology. The company’s current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation.
